贝瑞基因2024年净亏损1.92亿元 市场竞争加剧

Core Insights - Berry Genomics reported a revenue of 1.078 billion yuan for 2024, a year-on-year decrease of 6.36% [1] - The company achieved a net loss attributable to shareholders of 192 million yuan, a reduction in loss by 54.96% year-on-year [1] - Basic earnings per share were -0.54 yuan, with a weighted average return on equity of -10.87% [1] Financial Performance - Total operating expenses for 2024 amounted to 488 million yuan, with sales expenses decreasing by 19.02% and management expenses slightly increasing by 5.05% [3] - Research and development expenses fell by 13.26%, while financial expenses decreased by 48.94% due to debt optimization [3] - Net cash flow from operating activities was 87.96 million yuan, a year-on-year decrease of 20.75% [3] Revenue Breakdown - In 2024, revenue from reagent sales was 475 million yuan, a slight increase of 2.05%, accounting for 44.10% of total revenue [3] - Medical testing services contributed 35.26%, while basic research services accounted for 15.07% [3] - Equipment sales and other businesses made up 3.77% and 1.81% respectively, indicating that reagent sales and medical testing services remain the main revenue pillars despite increased market competition [3] Strategic Developments - Berry Genomics focused on optimizing product structure to enhance gross margins, with new prenatal and newborn screening products launched in 2023 supporting long-term growth potential [3] - Research and development expenses for 2024 were 113 million yuan, representing 10.53% of revenue, with advancements in third-generation sequencing technology for thalassemia testing [3] - The company established a joint venture with Saudi Arabian Ajlan Brothers Medical Company in 2023, focusing on reproductive health testing in the Middle East, and continued to advance local laboratory construction and product implementation in 2024 [3]